Hypervirulent clostridium difficile pcr-ribotypes exhibit resistance to widely used disinfectants

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Dawson, Lisa F ^a   Valiente, Esmeralda ^a   Donahue, Elizabeth H ^a   Birchenough, George ^a   Wren, Brendan W ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE DERIVATIVE; BIOCLENSE; CHLORHEXIDINE GLUCONATE; CHLORINE RELEASING AGENT; DISINFECTANT AGENT; HAZTAB; NEWGENN; PERASAFE; PEROXYGEN DERIVATIVE; PROCEINE 40; QUATERNARY AMMONIUM DERIVATIVE; SODIUM THIOSULFATE; STERI7; UNCLASSIFIED DRUG; VIRKON;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; CLOSTRIDIUM DIFFICILE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISINFECTION; LIMIT OF DETECTION; NONHUMAN; POLYMERASE CHAIN REACTION; SPORE GERMINATION; DRUG EFFECT; GENETICS; METHODOLOGY; PATHOGENICITY; VIRULENCE;

CLOSTRIDIUM DIFFICILE;

CLOSTRIDIUM DIFFICILE; DISINFECTANTS; DRUG RESISTANCE, MICROBIAL; POLYMERASE CHAIN REACTION; VIRULENCE;

EID: 80055045801     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025754     Document Type: Article

References (44)

1. Bartlett J, (1994) Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 18: S265-272.
2. Hubert B, Loo V, Bourgault A, Poirier L, Dascal A, et al. (2007) A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis 44: 238-244.
3. Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, et al. (2008) Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 47: 1162-1170.
4. Clements AC, Magalhaes RJ, Tatem AJ, Paterson DL, Riley TV, (2010) Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 10: 395-404.
5. Stabler RA, Gerding DN, Songer JG, Drudy D, Brazier JS, et al. (2006) Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains. J Bacteriol 188: 7297-7305.
6. Dingle KE, Griffiths D, Didelot X, Evans J, Vaughan A, et al. (2011) Clinical Clostridium difficile: clonality and pathogenicity locus diversity. PLoS ONE 6: e19993.
7. He M, Sebaihia M, Lawley TD, Stabler RA, Dawson LF, et al. (2010) Evolutionary dynamics of Clostridium difficile over short and long time scales. Proc Natl Acad Sci U S A 107: 7527-7532.
8. Loo V, Poirier L, Miller M, Oughton M, Libman M, et al. (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353: 2442-2449.
9. Pepin J, Valiquette L, Cossette B, (2005) Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. Cmaj 173: 1037-1042.
10. Bartlett JG, (1994) Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 18 (Suppl 4): S265-272.
11. Kuijper EJ, van Dissel JT, Wilcox MH, (2007) Clostridium difficile: changing epidemiology and new treatment options. Curr Opin Infect Dis 20: 376-383.
12. Mulligan ME, Citron D, Gabay E, Kirby BD, George WL, et al. (1984) Alterations in human fecal flora, including ingrowth of Clostridium difficile, related to cefoxitin therapy. Antimicrob Agents Chemother 26: 343-346.
13. Best EL, Fawley WN, Parnell P, Wilcox MH, (2010) The Potential for Airborne Dispersal of Clostridium difficile from Symptomatic Patients. Clinical Infectious Diseases 50: 1450-1457.
14. Mulligan M, George W, Rolfe R, Finegold S, (1980) Epidemiological aspects of Clostridium difficile-induced diarrhea and colitis. The American Journal of Clinical Nutrition 33: 2533-2538.
15. Vrtis MC, (2008) Clostridium difficile: preventing epidemic outbreaks in home health. Home Healthc Nurse 26: 563-569; quiz 570-561.
16. Samore MH, Venkataraman L, DeGirolami PC, Arbeit RD, Karchmer AW, (1996) Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med 100: 32-40.
17. Kim KH, Fekety R, Batts DH, Brown D, Cudmore M, et al. (1981) Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 143: 42-50.
18. Fekety R, Kim KH, Brown D, Batts DH, Cudmore M, et al. (1981) Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment. Am J Med 70: 906-908.
19. Settle CD, Wilcox MH, (2008) Clostridium difficile and chlorine-releasing disinfectants. Lancet 371: 810.
20. Shapey S, Machin K, Levi K, Boswell TC, (2008) Activity of a dry mist hydrogen peroxide system against environmental Clostridium difficile contamination in elderly care wards. Journal of Hospital Infection 70: 136-141.
21. Wilcox MH, Fawley WN, Wigglesworth N, Parnell P, Verity P, et al. (2003) Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect 54: 109-114.
22. Russell AD, Suller MT, Maillard JY, (1999) Do antiseptics and disinfectants select for antibiotic resistance? J Med Microbiol 48: 613-615.
23. McMurry LM, Oethinger M, Levy SB, (1998) Overexpression of marA, soxS, or acrAB produces resistance to triclosan in laboratory and clinical strains of Escherichia coli. FEMS Microbiol Lett 166: 305-309.
24. Bartlett J, (2008) Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 46: S4-11.
25. Drudy D, Quinn T, O'Mahony R, Kyne L, O'Gaora P, et al. (2006) High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother.
26. Spigaglia P, Barbanti F, Mastrantonio P, Brazier JS, Barbut F, et al. (2008) Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 57: 784-789.
27. Wust J, Sullivan NM, Hardegger U, Wilkins TD, (1982) Investigation of an outbreak of antibiotic-associated colitis by various typing methods. J Clin Microbiol 16: 1096-1101.
28. Sebaihia M, Wren BW, Mullany P, Fairweather NF, Minton N, et al. (2006) The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 38: 779-786.
29. McFarland LV, Mulligan ME, Kwok RY, Stamm WE, (1989) Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320: 204-210.
30. O'Neill G, Adams JE, Bowman RA, Riley TV, (1993) A molecular characterization of Clostridium difficile isolates from humans, animals and their environments. Epidemiol Infect 111: 257-264.
31. Fraise AP, (2002) Biocide abuse and antimicrobial resistance-a cause for concern? J Antimicrob Chemother 49: 11-12.
32. Levy SB, (2000) Antibiotic and antiseptic resistance: impact on public health. Pediatr Infect Dis J 19: S120-122.
33. Schweizer HP, (2001) Triclosan: a widely used biocide and its link to antibiotics. FEMS Microbiol Lett 202: 1-7.
34. McBain AJ, Bartolo RG, Catrenich CE, Charbonneau D, Ledder RG, et al. (2003) Effects of a chlorhexidine gluconate-containing mouthwash on the vitality and antimicrobial susceptibility of in vitro oral bacterial ecosystems. Appl Environ Microbiol 69: 4770-4776.
35. Thomas L, Russell AD, Maillard J-Y, (2005) Antimicrobial activity of chlorhexidine diacetate and benzalkonium chloride against Pseudomonas aeruginosa and its response to biocide residues. Journal of Applied Microbiology 98: 533-543.
36. Malamou-Ladas H, O'Farrell S, Nash JQ, Tabaqchali S, (1983) Isolation of Clostridium difficile from patients and the environment of hospital wards. J Clin Pathol 36: 88-92.
37. Hota B, (2004) Contamination, disinfection, and cross-colonization: are hospital surfaces reservoirs for nosocomial infection? Clin Infect Dis 39: 1182-1189.
38. Lawley TD, Clare S, Deakin LJ, Goulding D, Yen JL, et al. (2010) Use of purified Clostridium difficile spores to facilitate evaluation of health care disinfection regimens. Appl Environ Microbiol 76: 6895-6900.
39. Russell AD, (2003) Biocide use and antibiotic resistance: the relevance of laboratory findings to clinical and environmental situations. The Lancet Infectious Diseases 3: 794-803.
40. Ceragioli M, Mols M, Moezelaar R, Ghelardi E, Senesi S, et al. (2010) Comparative transcriptome and phenotype analysis of Bacillus cereus in response to disinfectant treatments. Appl Environ Microbiol.
41. Block S, eds. (1991) Peroxygen compounds. 4 ed. Philadelphia Lae and Febiger pp. 167-181.
42. Kulikovsky A, Pankratz HS, Sadoff HL, (1975) Ultrastructural and chemical changes in spores of Bacillus cereus after action of disinfectants. J Appl Bacteriol 38: 39-46.
43. Ny O, Pituch H, Mat?jková J, Obuch-Woszczatynski P, Kuijper EJ, (2011) Clostridium difficile PCR ribotype 176 in the Czech Republic and Poland. The Lancet 377: 1407.
44. Stabler R, He M, Dawson L, Martin M, Valiente E, et al. (2009) Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biology 10: R102.